Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | NQO1 | P15559 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 2/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989333 | 0.89 | KDM4E (0.51) | MAP4K4SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL30228475 | 0.89 | KDM4E (0.66) | SMN1; SMN2RAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL5682765 | 0.89 | KDM4E (0.66) | SMN1; SMN2RAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL13399134 | 0.88 | MAP4K4 (0.52) | MAP4K4SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL6851588 | 0.87 | RAB9A (0.69) | MAP4K4SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL29746123 | 0.87 | RAB9A (0.69) | MAP4K4SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL6858239 | 0.86 | RAB9A (0.67) | MAP4K4SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL13870935 | 0.86 | PDGFRB (0.61) | MAP4K4SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL4486496 | 0.85 | KDM4E (0.70) | SMN1; SMN2RAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL13870903 | 0.84 | MAP4K4 (0.51) | MAP4K4SMN1; SMN2RAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2131826-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008116920-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116920-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2008-10-02 | — | — | WO | disclosed |
| US-7056931-B2 | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1395563-B1 | 2-SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES AND DERIVATIVES THEREOF, COMPOSITIONS AND METHODS | LILLY CO ELI (US) | 2006-03-29 | — | — | EP | disclosed |
| US-6962928-B2 | Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis | ELI LILLY AND COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1401446-B1 | TETRAHYDROQUINOLIN DERIVATIVES FOR THE INHIBITION OF DISEASES ASSOCIATED WITH ESTROGEN DEPRIVATION OR WITH AN ABERRANT PHYSIOLOGICAL RESPONSE TO ENDOGENOUS ESTROGEN | LILLY CO ELI (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040215018-A1 | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods | WALLACE OWEN BRENDAN (US) | 2004-10-28 | — | — | US | disclosed |
| US-20040132770-A1 | Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen | ELI LILLY AND COMPANY | 2004-07-08 | — | — | US | disclosed |
| EP-1401446-A1 | TETRAHYDROQUINOLIN DERIVATIVES FOR THE INHIBITION OF DISEASES ASSOCIATED WITH ESTROGEN DEPRIVATION OR WITH AN ABERRANT PHYSIOLOGICAL RESPONSE TO ENDOGENOUS ESTROGEN | ELI LILLY AND COMPANY (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1395563-A1 | 2-SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES AND DERIVATIVES THEREOF, COMPOSITIONS AND METHODS | ELI LILLY AND COMPANY (US) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094268-A1 | TETRAHYDROQUINOLIN DERIVATIVES FOR THE INHIBITION OF DISEASES ASSOCIATED WITH ESTROGEN DEPRIVATION OR WITH AN ABERRANT PHYSIOLOGICAL RESPONSE TO ENDOGENOUS ESTROGEN | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094788-A1 | 2-SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES AND DERIVATIVES THEREOF, COMPOSITIONS AND METHODS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132770-A1 | Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen | ESR2, ESR1, GPER1 | MAP4K4 900/4885SMN1; SMN2 3059/4885RAB9A 1993/4885 |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | HSD17B1, HSD17B11, HSD17B2 | MAP4K4 3054/4885SMN1; SMN2 2510/4885RAB9A 3773/4885 |
| US-20040215018-A1 | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods | CYP19A1, ESR2, NR5A1 | MAP4K4 1315/4885SMN1; SMN2 3304/4885RAB9A 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.